Domperidone Maleate
💊 Brand Formulations & Prices
220 brands sorted by unit price
Bpdon
Motodon
Motodon
P-Don
Dedom
Remadon
Adegut
Adorex
Anet
Apedom
Atidon
Bedom
Beridom
Cpdom
D-Peridone
DP-Done
Degut
Domp
Dompa
Dompen
Domperid
Domperidon
Domperon
Domstal
Doperon
Dopon
Edone
Emedon
Gidora
I-POP
Loridon
Merin
Motilium
Motiper
Myodon
Nudom
Omid
Omidon D
Peri
Pradom
Sydon
Virdon
Vomino
Xepadon
Gidonic
Loval
Motigen
Motil
Prokinet
Sandom
Regut
Dominat
Domsil
Perion
Domerin
Domfix
Domigut
Dominaaf
Dompi
Emidom
Eridon
Makdom
Moticare
Nudon
Perigut
Peristal
Ridon
SB-Dom
Sagdon
Umodin
Normogut
Almigut
Apidone
Domidon
Dompa-S
Dopadon
Dopagut
Dopatic
Egut
Filadon
Fixgut
Gardi
Motilex
Motiwin
Paridon
Ridon Fast
Veridom
Vesidon
Vomidon
Vomitop
Don-A
Apuldon
Avomit
Cosy
Deflux Meltab
Domar
Dometic
Domin
Domiren
Domixon
Doridon
Dysnov
Esogut
Omidon
Orbidon
Benidon
Deflux
Domaid
Domilin
Domilux
Dominol
Dudon
Gutset
Milium
Motigut
Noburn
Vave
Xeridon
Efodio
Xepadon
Deflux
Loridon
Adorex
Sandom
Dysnov
Apuldon
Domfix
Domilux
Domin
Dominol
Domiren
Don-A
Dopadon
Doridon
Esogut
Gutset
Myodon
Omidon
Vomitop
Xepadon
Motigut
Vave
Apedom
Dominat
P-Don
Adegut
Atidon
Bedom
Beridom
DP-Done
Dedom
Dompa-S
Domperon
Domsil
Domstal
Gidonic
Loridon
Motil
Motiper
Omid
Perigut
Virdon
Vomino
Motigen
Adorex
Emidom
Sandom
Cosy
Doperon
Loval
Domp
Dudon
Gidora
Edone
Esogut
Motiwin
Perion
Anet
Apuldon
Domfix
Domidon
Domin
Dominaaf
Dominol
Domiren
Dopagut
Motilium
Peri
Peristal
Ridon
Vomitop
Vave
Dopadon
Fixgut
Apidone
Dometic
Merin
Paridon
Avomit
Benidon
Domaid
Domar
Domilux
Don-A
Dopatic
Dysnov
Egut
Motigut
Motilex
Noburn
Normogut
Omidon
Prokinet
Xeridon
Gutset
Dompi
Deflux
Domilin
Efodio
Ridon EG
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAdegut is indicated in-
Dyspeptic symptom complex
, often associated with delayed gastric emptying, gastroesophageal reflux and esophagitis:
Epigastric sense of fullness, feeling of abdominal distension, upper abdominal pain
Eructation, flatulence, early satiety
Nausea and vomiting
Heartburn with or without regurgitations of gastric contents in the mouth
Non-ulcer dyspepsia
Acute nausea and vomiting
of the functional, organic, infectious, dietetic origin or induced by radiotherapy or drug therapy or induced in migraine.
Parkinson's disease
: In dopamine-agonist induced nausea and vomiting.
Radiological studies
: Speeding barium transit in follow-through radiological studies.
Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring.
The usual recommended oral dose of Domperidone is as follows:
Adults
: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily. The maximum dose of Domperidone is 80 mg daily.
Children
: 2-4 ml suspension/10 kg body weight or 0.4-0.8 ml paediatric drops/10 kg body weight, every 6-8 hours daily.
In dyspeptic symptom:
Adults
: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily.
Children
: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily.
In acute and sub-acute conditions (mainly in acute nausea and vomiting):
Adults
: 20 mg (2 tablets or 20 ml suspension), every 6-8 hours daily
Children
: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily. (In acute nausea and vomiting maximum period of treatment is 12 weeks).
By rectum in suppositories:
Adults (including elderly)
: 30-60 mg every 4-8 hours.
Children
: The maximum daily dose rectally in children's is 30 mg for those weighting 10 to 25 kg. The dose may be divided throughout day if necessary.
The maximum period of treatment is 12 weeks.
Domperidone is contraindicated to patients having known hypersensitivity to this drug and in the case of neonates. Domperidone should not be used whenever gastrointestinal stimulation might be dangerous i.e., gastrointestinal hemorrhage, mechanical obstruction or perforation. Also contraindicated in patients with prolactin releasing pituitary tumor (prolactinoma).
Side-effects are rare; exceptionally some transient intestinal cramps have been reported. Extrapyramidal phenomena are rare in young children and exceptional in adults: they reverse spontaneously and completely as soon as the treatment is stopped. As the pituitary gland is located outside the blood-brain barrier, domperidone may induce an increase in the plasma prolactin level. In rare case this hyperprolactinaemia may give rise to neuroendocrinological phenomena such as galactorrhoea and gynaecomastia. When the blood-brain barrier is immature (as in infants) or impaired, the possible occurrence of neurological side-effects cannot be totally excluded. Rare allergic reactions, such as rash and urticaria, have also been reported.
Adegut should be used with absolute caution in the case of children because there may be an increased risk of extra-pyramidal reactions in young children because of an incompletely developed blood-brain barrier. Since domperidone is highly metabolized in liver, it should be used with caution in patient with hepatic impairment.
Domperidone is a dopamine antagonist that principally blocks the dopamine receptors located in the ChemoreceptorTrigger Zone (CTZ) and stomach. Its gastroprokinetic action is based on its blocking effect of dopamine receptors that have an influence on the motility of the gastrointestinal tract. Due to its weak penetration across the blood-brain barrier, Domperidone has almost no effect on the dopaminergic receptors in the brain, therefore, excluding psychotropic and neurologic side effects. Domperidone restores normal motility and tone of the upper gastrointestinal tract, facilitates gastric emptying, enhances antral and duodenal peristalsis and regulates contraction of the pylorus. Domperidone also increases esophageal peristalsis and lower esophageal sphincter pressure, and thus prevents regurgitation of gastric content.